Holen Sie sich die Stockscreener-App
3.25
0.31%
0.010
Handel nachbörslich:
3.29
0.04
+1.23%
Schlusskurs vom Vortag:
$3.24
Offen:
$3.25
24-Stunden-Volumen:
2.50M
Relative Volume:
0.61
Marktkapitalisierung:
$707.53M
Einnahmen:
$35.54M
Nettoeinkommen (Verlust:
$-59.14M
KGV:
-8.9359
EPS:
-0.3637
Netto-Cashflow:
$-80.19M
1W Leistung:
-7.67%
1M Leistung:
-4.41%
6M Leistung:
-45.19%
1J Leistung:
+35.42%
1-Tages-Spanne:
$3.25
$3.43
1-Wochen-Bereich:
$3.20
$3.545
52-Wochen-Spanne:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.25 | 705.36M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2026-01-20 | Eingeleitet | Guggenheim | Buy |
| 2025-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com Canada
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times
Charles Fuchs appointed to CytomX Board as Class II director - TradingView
More Than Three Decades in Oncology: Fuchs Joins CytomX Board - Stock Titan
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CTMX|CytomX Therapeutics Inc|Price:3.240|Chg%:-0.090 - TradingKey
TradingKey - TradingKey
CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CTMX stock holds focus after CytomX strategy update - Ad-hoc-news.de
CytomX Therapeutics, Inc.Common Stock (NQ: CTMX - FinancialContent
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
CytomX Therapeutics (CTMX) Holds Near Support After Slight DipUpthrust Pattern - dars.gov.et
CytomX Therapeutics updates investors on its pipeline progress amid Nasdaq listing - Ad-hoc-news.de
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why - Yahoo Finance
CytomX Therapeutics focuses on its antibody-drug conjugate platform - Ad-hoc-news.de
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CytomX Therapeutics outlines its oncology focus as investors watch Nasdaq trading - ad-hoc-news.de
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to earnings forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView
CTMX Forecast — Price Target — Prediction for 2027 - TradingView
CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail
Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com India
CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart
CytomX Therapeutics stockholders approve share increases and board elections - Investing.com
CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada
Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan
[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan
Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan
Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan
CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan
CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan
CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):